Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 137

1.

Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.

White-Koning M, Osborne C, Paci A, Boddy AV, Chatelut E, Veal GJ.

Eur J Cancer. 2018 Mar;91:56-67. doi: 10.1016/j.ejca.2017.11.029. Epub 2018 Jan 12.

2.

Curcumin as a clinically-promising anti-cancer agent: pharmacokinetics and drug interactions.

Adiwidjaja J, McLachlan AJ, Boddy AV.

Expert Opin Drug Metab Toxicol. 2017 Sep;13(9):953-972. doi: 10.1080/17425255.2017.1360279. Epub 2017 Aug 10. Review.

PMID:
28776444
3.

A population pharmacokinetic model of AT9283 in adults and children to predict the maximum tolerated dose in children with leukaemia.

Duong JK, Griffin MJ, Hargrave D, Vormoor J, Edwards D, Boddy AV.

Br J Clin Pharmacol. 2017 Aug;83(8):1713-1722. doi: 10.1111/bcp.13260. Epub 2017 Mar 5.

PMID:
28177130
4.

Investigating the heterogeneity of alkylating agents' efficacy and toxicity between sexes: A systematic review and meta-analysis of randomized trials comparing cyclophosphamide and ifosfamide (MAIAGE study).

Fresneau B, Hackshaw A, Hawkins DS, Paulussen M, Anderson JR, Judson I, Litière S, Dirksen U, Lewis I, van den Berg H, Gaspar N, Gelderblom H, Whelan J, Boddy AV, Wheatley K, Pignon JP, De Vathaire F, Le Deley MC, Le Teuff G.

Pediatr Blood Cancer. 2017 Aug;64(8). doi: 10.1002/pbc.26457. Epub 2017 Jan 23. Review.

PMID:
28111876
5.

Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide.

Jamieson D, Sunter N, Muro S, Pouché L, Cresti N, Lee J, Sludden J, Griffin MJ, Allan JM, Verrill MW, Boddy AV.

Eur J Cancer. 2017 Jan;71:15-24. doi: 10.1016/j.ejca.2016.10.035. Epub 2016 Dec 8.

PMID:
27940354
6.

A phase I/II trial of AT9283, a selective inhibitor of aurora kinase in children with relapsed or refractory acute leukemia: challenges to run early phase clinical trials for children with leukemia.

Vormoor B, Veal GJ, Griffin MJ, Boddy AV, Irving J, Minto L, Case M, Banerji U, Swales KE, Tall JR, Moore AS, Toguchi M, Acton G, Dyer K, Schwab C, Harrison CJ, Grainger JD, Lancaster D, Kearns P, Hargrave D, Vormoor J.

Pediatr Blood Cancer. 2017 Jun;64(6). doi: 10.1002/pbc.26351. Epub 2016 Dec 1.

PMID:
27905678
7.

Pharmacokinetics of dabrafenib in a patient with metastatic melanoma undergoing haemodialysis.

Park JJ, Boddy AV, Liu X, Harris D, Lee V, Kefford RF, Carlino MS.

Pigment Cell Melanoma Res. 2017 Jan;30(1):68-71. doi: 10.1111/pcmr.12557.

PMID:
27863085
8.

The path to implementation of personalized medicine of aromatase inhibitors in patients with breast cancer.

Liu X, Beith J, Low SK, Boddy AV.

Pharmacogenomics. 2016 Oct 28. [Epub ahead of print] No abstract available.

9.

Pharmacokinetic and pharmacodynamic study of doxorubicin in children with cancer: results of a "European Pediatric Oncology Off-patents Medicines Consortium" trial.

Krischke M, Hempel G, Völler S, André N, D'Incalci M, Bisogno G, Köpcke W, Borowski M, Herold R, Boddy AV, Boos J.

Cancer Chemother Pharmacol. 2016 Dec;78(6):1175-1184. Epub 2016 Oct 21.

10.

A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours.

Jamieson D, Griffin MJ, Sludden J, Drew Y, Cresti N, Swales K, Merriman M, Allen R, Bevan P, Buerkle M, Mala C, Coyle V, Rodgers L, Dean E, Greystoke A, Banerji U, Wilson RH, Evans TR, Anthoney A, Ranson M, Boddy AV, Plummer R.

Eur J Cancer. 2016 Nov;68:1-10. doi: 10.1016/j.ejca.2016.08.026. Epub 2016 Sep 28.

PMID:
27693888
11.

Towards a Model-Based Dose Recommendation for Doxorubicin in Children.

Völler S, Hempel G, Würthwein G, Boddy AV, Krischke M, André N, D'Incalci M, Bisogno G, Boos J.

Clin Pharmacokinet. 2017 Mar;56(3):215-223. doi: 10.1007/s40262-016-0451-y.

12.

Plasma Retinol Kinetics and β-Carotene Bioefficacy Are Quantified by Model-Based Compartmental Analysis in Healthy Young Adults with Low Vitamin A Stores.

Green MH, Ford JL, Oxley A, Green JB, Park H, Berry P, Boddy AV, Lietz G.

J Nutr. 2016 Oct;146(10):2129-2136. Epub 2016 Aug 10.

13.

A Retinol Isotope Dilution Equation Predicts Both Group and Individual Total Body Vitamin A Stores in Adults Based on Data from an Early Postdosing Blood Sample.

Green MH, Ford JL, Green JB, Berry P, Boddy AV, Oxley A, Lietz G.

J Nutr. 2016 Oct;146(10):2137-2142. Epub 2016 Aug 10.

14.

Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.

Goulooze SC, Galettis P, Boddy AV, Martin JH.

Cancer Chemother Pharmacol. 2016 Jul;78(1):209-16. doi: 10.1007/s00280-016-3071-1. Epub 2016 Jun 13.

PMID:
27295055
15.

The implications of genetic variation for the pharmacokinetics and pharmacodynamics of aromatase inhibitors.

Liu X, Low SK, Boddy AV.

Expert Opin Drug Metab Toxicol. 2016 Aug;12(8):851-63. doi: 10.1080/17425255.2016.1196189. Epub 2016 Jun 16. Review.

PMID:
27253864
16.

Imagestream detection and characterisation of circulating tumour cells - A liquid biopsy for hepatocellular carcinoma?

Ogle LF, Orr JG, Willoughby CE, Hutton C, McPherson S, Plummer R, Boddy AV, Curtin NJ, Jamieson D, Reeves HL.

J Hepatol. 2016 Aug;65(2):305-13. doi: 10.1016/j.jhep.2016.04.014. Epub 2016 Apr 27.

PMID:
27132171
17.

Cyclophosphamide pharmacokinetics and pharmacogenetics in children with B-cell non-Hodgkin's lymphoma.

Veal GJ, Cole M, Chinnaswamy G, Sludden J, Jamieson D, Errington J, Malik G, Hill CR, Chamberlain T, Boddy AV.

Eur J Cancer. 2016 Mar;55:56-64. doi: 10.1016/j.ejca.2015.12.007. Epub 2016 Jan 12.

18.

Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer.

Cresti N, Lee J, Rourke E, Televantou D, Jamieson D, Verrill M, Boddy AV.

Eur J Cancer. 2016 Mar;55:27-37. doi: 10.1016/j.ejca.2015.10.066. Epub 2016 Jan 8.

PMID:
26773371
19.

Development of a physiologically based pharmacokinetic model of actinomycin D in children with cancer.

Walsh C, Bonner JJ, Johnson TN, Neuhoff S, Ghazaly EA, Gribben JG, Boddy AV, Veal GJ.

Br J Clin Pharmacol. 2016 May;81(5):989-98. doi: 10.1111/bcp.12878. Epub 2016 Feb 25.

20.

Efficacy of PARP Inhibitor Rucaparib in Orthotopic Glioblastoma Xenografts Is Limited by Ineffective Drug Penetration into the Central Nervous System.

Parrish KE, Cen L, Murray J, Calligaris D, Kizilbash S, Mittapalli RK, Carlson BL, Schroeder MA, Sludden J, Boddy AV, Agar NY, Curtin NJ, Elmquist WF, Sarkaria JN.

Mol Cancer Ther. 2015 Dec;14(12):2735-43. doi: 10.1158/1535-7163.MCT-15-0553. Epub 2015 Oct 5.

21.

Formulation of Biologically-Inspired Silk-Based Drug Carriers for Pulmonary Delivery Targeted for Lung Cancer.

Kim SY, Naskar D, Kundu SC, Bishop DP, Doble PA, Boddy AV, Chan HK, Wall IB, Chrzanowski W.

Sci Rep. 2015 Aug 3;5:11878. doi: 10.1038/srep11878.

22.

High-resolution imaging for the detection and characterisation of circulating tumour cells from patients with oesophageal, hepatocellular, thyroid and ovarian cancers.

Dent BM, Ogle LF, O'Donnell RL, Hayes N, Malik U, Curtin NJ, Boddy AV, Plummer ER, Edmondson RJ, Reeves HL, May FE, Jamieson D.

Int J Cancer. 2016 Jan 1;138(1):206-16. doi: 10.1002/ijc.29680. Epub 2015 Aug 19.

23.

Age-Dependent Pharmacokinetics of Doxorubicin in Children with Cancer.

Völler S, Boos J, Krischke M, Würthwein G, Kontny NE, Boddy AV, Hempel G.

Clin Pharmacokinet. 2015 Nov;54(11):1139-49. doi: 10.1007/s40262-015-0272-4.

PMID:
25925711
24.

A phase I trial of AT9283 (a selective inhibitor of aurora kinases) in children and adolescents with solid tumors: a Cancer Research UK study.

Moreno L, Marshall LV, Pearson AD, Morland B, Elliott M, Campbell-Hewson Q, Makin G, Halford SE, Acton G, Ross P, Kazmi-Stokes S, Lock V, Rodriguez A, Lyons JF, Boddy AV, Griffin MJ, Yule M, Hargrave D.

Clin Cancer Res. 2015 Jan 15;21(2):267-73. doi: 10.1158/1078-0432.CCR-14-1592. Epub 2014 Nov 4.

25.

Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil.

Jamieson D, Lee J, Cresti N, Jackson R, Griffin M, Sludden J, Verrill M, Boddy AV.

Cancer Chemother Pharmacol. 2014 Oct;74(4):667-74. doi: 10.1007/s00280-014-2541-6. Epub 2014 Jul 24.

PMID:
25055937
26.

Characterisation of the clinical pharmacokinetics of actinomycin D and the influence of ABCB1 pharmacogenetic variation on actinomycin D disposition in children with cancer.

Hill CR, Cole M, Errington J, Malik G, Boddy AV, Veal GJ.

Clin Pharmacokinet. 2014 Aug;53(8):741-51. doi: 10.1007/s40262-014-0153-2.

27.

Sources of preanalytical error in pharmacokinetic analyses - focus on intravenous drug administration and collection of blood samples.

Krischke M, Boddy AV, Boos J.

Expert Opin Drug Metab Toxicol. 2014 Jun;10(6):825-38. doi: 10.1517/17425255.2014.907273. Epub 2014 Apr 16. Review.

PMID:
24738965
28.

Tumour cell retention of rucaparib, sustained PARP inhibition and efficacy of weekly as well as daily schedules.

Murray J, Thomas H, Berry P, Kyle S, Patterson M, Jones C, Los G, Hostomsky Z, Plummer ER, Boddy AV, Curtin NJ.

Br J Cancer. 2014 Apr 15;110(8):1977-84. doi: 10.1038/bjc.2014.91. Epub 2014 Feb 20.

29.

An LC/MS/MS method for stable isotope dilution studies of β-carotene bioavailability, bioconversion, and vitamin A status in humans.

Oxley A, Berry P, Taylor GA, Cowell J, Hall MJ, Hesketh J, Lietz G, Boddy AV.

J Lipid Res. 2014 Feb;55(2):319-28. doi: 10.1194/jlr.D040204. Epub 2013 Oct 24.

30.

Genetics of cisplatin ototoxicity: confirming the unexplained?

Boddy AV.

Clin Pharmacol Ther. 2013 Aug;94(2):198-200. doi: 10.1038/clpt.2013.116.

PMID:
23872836
31.

Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.

Kontny NE, Würthwein G, Joachim B, Boddy AV, Krischke M, Fuhr U, Thompson PA, Jörger M, Schellens JH, Hempel G.

Cancer Chemother Pharmacol. 2013 Mar;71(3):749-63. doi: 10.1007/s00280-013-2069-1. Epub 2013 Jan 13.

PMID:
23314734
32.

Adaptive dosing approaches to the individualization of 13-cis-retinoic acid (isotretinoin) treatment for children with high-risk neuroblastoma.

Veal GJ, Errington J, Rowbotham SE, Illingworth NA, Malik G, Cole M, Daly AK, Pearson AD, Boddy AV.

Clin Cancer Res. 2013 Jan 15;19(2):469-79. doi: 10.1158/1078-0432.CCR-12-2225. Epub 2012 Oct 19.

33.

Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.

Hill CR, Jamieson D, Thomas HD, Brown CD, Boddy AV, Veal GJ.

Biochem Pharmacol. 2013 Jan 1;85(1):29-37. doi: 10.1016/j.bcp.2012.10.004. Epub 2012 Oct 11.

34.

Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring.

Veal GJ, Boddy AV.

J Clin Oncol. 2012 Sep 20;30(27):3424; author reply 3425. doi: 10.1200/JCO.2012.43.5677. Epub 2012 Jul 30. No abstract available.

PMID:
22851560
35.

Minimization of the preanalytical error in pharmacokinetic analyses and therapeutic drug monitoring: focus on IV drug administration.

Kontny NE, Boos J, Würthwein G, Hempel G, Boddy AV, Groll AH, Krischke M.

Ther Drug Monit. 2012 Aug;34(4):460-6. doi: 10.1097/FTD.0b013e31825a4d9c.

PMID:
22660605
36.

Chemotherapy in newborns and preterm babies.

Veal GJ, Boddy AV.

Semin Fetal Neonatal Med. 2012 Aug;17(4):243-8. doi: 10.1016/j.siny.2012.03.002. Epub 2012 Mar 28. Review.

PMID:
22464845
37.

Minimization of the preanalytical error in plasma samples for pharmacokinetic analyses and therapeutic drug monitoring--using doxorubicin as an example.

Kontny NE, Hempel G, Boos J, Boddy AV, Krischke M.

Ther Drug Monit. 2011 Dec;33(6):766-71. doi: 10.1097/FTD.0b013e31823aa8ab.

PMID:
22105595
38.

Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues.

Jarvis IW, Meczes EL, Thomas HD, Edmondson RJ, Veal GJ, Boddy AV, Ottley CJ, Pearson DG, Tilby MJ.

Biochem Pharmacol. 2012 Jan 1;83(1):69-77. doi: 10.1016/j.bcp.2011.10.005. Epub 2011 Oct 14.

PMID:
22015635
39.

Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy.

Jamieson D, Cresti N, Bray J, Sludden J, Griffin MJ, Hawsawi NM, Famie E, Mould EV, Verrill MW, May FE, Boddy AV.

Pharmacogenet Genomics. 2011 Dec;21(12):808-19. doi: 10.1097/FPC.0b013e32834b6918.

PMID:
21946896
40.

Pharmacogenetics of genes across the doxorubicin pathway.

Jamieson D, Boddy AV.

Expert Opin Drug Metab Toxicol. 2011 Oct;7(10):1201-10. doi: 10.1517/17425255.2011.610180. Review.

PMID:
21919804
41.

Thiothymidine combined with UVA as a potential novel therapy for bladder cancer.

Pridgeon SW, Heer R, Taylor GA, Newell DR, O'Toole K, Robinson M, Xu YZ, Karran P, Boddy AV.

Br J Cancer. 2011 Jun 7;104(12):1869-76. doi: 10.1038/bjc.2011.180. Epub 2011 May 24.

42.

Pharmacokinetics of cyclophosphamide and its metabolites in paediatric patients receiving high-dose myeloablative therapy.

Chinnaswamy G, Errington J, Foot A, Boddy AV, Veal GJ, Cole M.

Eur J Cancer. 2011 Jul;47(10):1556-63. doi: 10.1016/j.ejca.2011.03.008. Epub 2011 Apr 7.

PMID:
21482104
43.

A Phase I clinical study of cisplatin-incorporated polymeric micelles (NC-6004) in patients with solid tumours.

Plummer R, Wilson RH, Calvert H, Boddy AV, Griffin M, Sludden J, Tilby MJ, Eatock M, Pearson DG, Ottley CJ, Matsumura Y, Kataoka K, Nishiya T.

Br J Cancer. 2011 Feb 15;104(4):593-8. doi: 10.1038/bjc.2011.6. Epub 2011 Feb 1.

44.

Characterization of the metabolism of fenretinide by human liver microsomes, cytochrome P450 enzymes and UDP-glucuronosyltransferases.

Illingworth NA, Boddy AV, Daly AK, Veal GJ.

Br J Pharmacol. 2011 Feb;162(4):989-99. doi: 10.1111/j.1476-5381.2010.01104.x.

45.

Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699.

Daniel RA, Rozanska AL, Mulligan EA, Drew Y, Thomas HD, Castelbuono DJ, Hostomsky Z, Plummer ER, Tweddle DA, Boddy AV, Clifford SC, Curtin NJ.

Br J Cancer. 2010 Nov 9;103(10):1588-96. doi: 10.1038/sj.bjc.6605946. Epub 2010 Oct 26.

46.

Relevance of nonsynonymous CYP2C8 polymorphisms to 13-cis retinoic acid and paclitaxel hydroxylation.

Rowbotham SE, Boddy AV, Redfern CP, Veal GJ, Daly AK.

Drug Metab Dispos. 2010 Aug;38(8):1261-6. doi: 10.1124/dmd.109.030866. Epub 2010 Apr 26.

47.

Malnourished Malawian patients presenting with large Wilms tumours have a decreased vincristine clearance rate.

Israels T, Damen CW, Cole M, van Geloven N, Boddy AV, Caron HN, Beijnen JH, Molyneux EM, Veal GJ.

Eur J Cancer. 2010 Jul;46(10):1841-7. doi: 10.1016/j.ejca.2010.03.002. Epub 2010 Apr 9.

PMID:
20382523
48.

Role of UDP-glucuronosyltransferase isoforms in 13-cis retinoic acid metabolism in humans.

Rowbotham SE, Illingworth NA, Daly AK, Veal GJ, Boddy AV.

Drug Metab Dispos. 2010 Jul;38(7):1211-7. doi: 10.1124/dmd.109.031625. Epub 2010 Mar 22.

49.

Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide.

Bray J, Sludden J, Griffin MJ, Cole M, Verrill M, Jamieson D, Boddy AV.

Br J Cancer. 2010 Mar 16;102(6):1003-9. doi: 10.1038/sj.bjc.6605587. Epub 2010 Feb 23.

50.

Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.

Veal GJ, Cole M, Errington J, Pearson AD, Gerrard M, Whyman G, Ellershaw C, Boddy AV.

Cancer Chemother Pharmacol. 2010 May;65(6):1057-66. doi: 10.1007/s00280-009-1111-9. Epub 2009 Aug 23.

PMID:
19701749

Supplemental Content

Loading ...
Support Center